Submitted by Annemieke DeMaggio on Tue, 08/25/2020 - 10:00
The phase 3 IDHENTIFY study failed to show OS benefit with enasidenib compared to standard treatment options in IDH2mut, r/r AML (BMS press release)
Submitted by Annemieke DeMaggio on Wed, 08/05/2020 - 10:32
The confirmatory CROWN study compared lorlatinib to crizotinib in tx-naïve, ALKpos NSCLC. The study met its’ primary endpoint (PFS by BIRC) at interim analysis. Data has not been presented (Pfizer press release).
